Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT. "Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults." HIV Clin Trials. 2015;16(2):66-71.
Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottilil S. "Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo." J AIDS Clin Res. 2015;6(1).
Henrich TJ, Lewine NRP, Lee S-H, et al. "Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists." Antimicrob. Agents Chemother.. 2012;56(4):1931-5.
Johs NA, Wu K, Tassiopoulos K, et al. "Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection." Clin. Infect. Dis.. 2017;65(1):83-91.
Snoeck J, Kantor R, Shafer RW, et al. "Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent." Antimicrob. Agents Chemother.. 2006;50(2):694-701.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Sun J, Nagaraj HN, Reynolds NR. "Discrete stochastic models for compliance analysis based on an AIDS Clinical Trial Group (ACTG) study." Biom J. 2007;49(5):731-41.
Rouabhia M, Semlali A, Chandra J, Mukherjee P, Chmielewski W, Ghannoum MA. "Disruption of the ECM33 gene in Candida albicans prevents biofilm formation, engineered human oral mucosa tissue damage and gingival cell necrosis/apoptosis." Mediators Inflamm.. 2012;2012:398207.
Bednar MM, Hauser BM, Zhou S, et al. "Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation." J. Infect. Dis.. 2016;214(3):403-7.
Schnitzer ME, Lok JJ, Bosch RJ. "Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring." Biostatistics. 2016;17(1):165-77.
Wallis CL, Aga E, Ribaudo H, et al. "Drug susceptibility and resistance mutations after first-line failure in resource limited settings." Clin. Infect. Dis.. 2014;59(5):706-15.
Wang R, Bosch RJ, Benson CA, Lederman MM. "Drug-resistant virus has reduced ability to induce immune activation." J. Acquir. Immune Defic. Syndr.. 2012;61(4):e60-3.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Koelsch KK, Liu L, Haubrich R, et al. "Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro." J. Infect. Dis.. 2008;197(3):411-9.
Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.


Sax PE, Sloan CE, Schackman BR, et al. "Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164." HIV Clin Trials. 2010;11(5):248-59.
Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLoS ONE. 2009;4(5):e5575.
Andrade A, Guedj J, Rosenkranz SL, et al. "Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)." AIDS. 2015;29(18):2419-26.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Simpson KN, Dietz B, Baran RW, et al. "Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data." Cost Eff Resour Alloc. 2011;9:5.
Marc LG, Testa MA, Walker AM, et al. "Educational attainment and response to HAART during initial therapy for HIV-1 infection." J Psychosom Res. 2007;63(2):207-16.
Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Bednasz CJ, Venuto CS, Ma Q, et al. "Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants." Ther Drug Monit. 2017;39(6):596-603.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Tenorio AR, Spritzler J, Martinson J, et al. "The effect of aging on T-regulatory cell frequency in HIV infection." Clin. Immunol.. 2009;130(3):298-303.
Geng EH, Kahn JS, Chang OC, et al. "The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation." Clin. Infect. Dis.. 2011;53(10):1008-14.
Stapleton JT, Bennett K, Bosch RJ, Polgreen PM, Swindells S. "Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy." HIV Clin Trials. 2007;8(6):429-36.
Gandhi RT, Spritzler J, Chan E, et al. "Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384." J. Acquir. Immune Defic. Syndr.. 2006;42(4):426-34.
Jacobson JM, Bosinger SE, Kang M, et al. "The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1." AIDS Res. Hum. Retroviruses. 2016;32(7):636-47.
Acosta EP, Kendall MA, Gerber JG, et al. "Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily." Antimicrob. Agents Chemother.. 2007;51(9):3104-10.